Stem definition | Drug id | CAS RN |
---|---|---|
platelet aggregation inhibitors | 209 | 68475-42-3 |
None
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.56 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 75 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 15, 2004 | EMA | SHIRE PHARMACEUTICALS IRELAND LIMITED | |
March 14, 1997 | FDA | SHIRE LLC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Platelet count increased | 106.69 | 31.48 | 31 | 1309 | 17680 | 63470002 |
Myelofibrosis | 97.87 | 31.48 | 18 | 1322 | 1359 | 63486323 |
Bone marrow reticulin fibrosis | 44.22 | 31.48 | 7 | 1333 | 214 | 63487468 |
Thrombocytosis | 38.61 | 31.48 | 11 | 1329 | 5807 | 63481875 |
Adenocarcinoma metastatic | 33.48 | 31.48 | 5 | 1335 | 103 | 63487579 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Platelet count increased | 52.89 | 27.70 | 17 | 1031 | 9509 | 34946374 |
Myelofibrosis | 32.96 | 27.70 | 8 | 1040 | 1603 | 34954280 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Platelet count increased | 112.32 | 26.87 | 36 | 2098 | 22370 | 79719884 |
Myelofibrosis | 66.31 | 26.87 | 15 | 2119 | 2485 | 79739769 |
Thrombocytosis | 52.29 | 26.87 | 16 | 2118 | 8510 | 79733744 |
Splenomegaly | 38.38 | 26.87 | 16 | 2118 | 20738 | 79721516 |
Bone marrow reticulin fibrosis | 32.79 | 26.87 | 6 | 2128 | 344 | 79741910 |
Stress cardiomyopathy | 32.65 | 26.87 | 12 | 2122 | 11154 | 79731100 |
Congestive cardiomyopathy | 32.02 | 26.87 | 12 | 2122 | 11768 | 79730486 |
Adenocarcinoma metastatic | 29.44 | 26.87 | 5 | 2129 | 186 | 79742068 |
Cardiac failure | 27.87 | 26.87 | 27 | 2107 | 154815 | 79587439 |
None
Source | Code | Description |
---|---|---|
ATC | L01XX35 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
FDA MoA | N0000175086 | Phosphodiesterase 3 Inhibitors |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D005343 | Fibrinolytic Agents |
MeSH PA | D006401 | Hematologic Agents |
MeSH PA | D010975 | Platelet Aggregation Inhibitors |
FDA EPC | N0000175638 | Platelet-reducing Agent |
FDA PE | N0000175972 | Decreased Platelet Production |
CHEBI has role | CHEBI:48675 | antifibrinolytic agent |
CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
CHEBI has role | CHEBI:35554 | cardiovascular agent |
CHEBI has role | CHEBI:50249 | anticoagulants |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Essential thrombocythemia | indication | 109994006 | DOID:2224 |
Thrombocytosis in Myeloproliferative Disease | indication | ||
High output heart failure | contraindication | 10091002 | |
Heart disease | contraindication | 56265001 | DOID:114 |
Hepatic failure | contraindication | 59927004 | |
Interstitial pneumonia | contraindication | 64667001 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Interstitial lung disease | contraindication | 233703007 | DOID:3082 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Eosinophilic asthma | contraindication | 367542003 | DOID:9498 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.12 | acidic |
pKa2 | 3.82 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Enzyme | INHIBITOR | IC50 | 7.27 | IUPHAR | CHEMBL | |||
cGMP-dependent 3',5'-cyclic phosphodiesterase | Enzyme | IC50 | 4.47 | CHEMBL |
ID | Source |
---|---|
4024077 | VUID |
N0000022082 | NUI |
D02933 | KEGG_DRUG |
823178-43-4 | SECONDARY_CAS_RN |
236612 | RXNORM |
C0051809 | UMLSCUI |
CHEBI:55345 | CHEBI |
J33 | PDB_CHEM_ID |
CHEMBL760 | ChEMBL_ID |
DB00261 | DRUGBANK_ID |
CHEMBL1200759 | ChEMBL_ID |
C021139 | MESH_SUPPLEMENTAL_RECORD_UI |
135409400 | PUBCHEM_CID |
7114 | IUPHAR_LIGAND_ID |
4672 | INN_ID |
K9X45X0051 | UNII |
4199 | MMSL |
58814 | MMSL |
d04126 | MMSL |
108976008 | SNOMEDCT_US |
108977004 | SNOMEDCT_US |
372561005 | SNOMEDCT_US |
4021052 | VANDF |
4024077 | VANDF |
006435 | NDDF |
006436 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Anagrelide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0172-5240 | CAPSULE | 1 mg | ORAL | ANDA | 26 sections |
Anagrelide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0172-5241 | CAPSULE | 0.50 mg | ORAL | ANDA | 26 sections |